[(1S,2S,3R,4aS,8aR)-3-amino-2,5,5,8a-tetramethyl-1,2,3,4,4a,6,7,8-octahydronaphthalen-1-yl]-(3-hydroxy-5-methylphenyl)methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(1S,2S,3R,4aS,8aR)-3-amino-2,5,5,8a-tetramethyl-1,2,3,4,4a,6,7,8-octahydronaphthalen-1-yl]-(3-hydroxy-5-methylphenyl)methanone
• 化学式: C₂₂H₃₃NO₂
• 分子量: 343.5
• InChiKey: ZLUBYVXMWQDIQY-MAEOEUOPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• SHIP1 MODULATORS AND METHODS RELATED THERETO
  申请人：AQUINOX PHARMACEUTICALS (CANADA) INC.

  公开号：US20160257671A2

  公开（公告）日：2016-09-08

  Compounds of formula (I): where n, R 1 , R 4a , R 4b , R 5 , R 7 and R 8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

  本文描述了化学式(I)的化合物，其中n，R1，R4a，R4b，R5，R7和R8在此定义，或其药学上可接受的盐。所披露的化合物具有SHIP1调节剂的活性，因此可用于治疗任何需要SHIP1调节的疾病、障碍或病况。本文还披露了包含化学式(I)化合物与药学上可接受的载体或稀释剂的组合物，以及通过向需要这些化合物的动物施用来进行SHIP1调节的方法。
• US9937167B2
  申请人：——

  公开号：US9937167B2

  公开（公告）日：2018-04-10
• [EN] SHIP1 MODULATORS AND METHODS RELATED THERETO<br/>[FR] MODULATEURS DE SHIP1 ET PROCÉDÉS ASSOCIÉS
  申请人：AQUINOX PHARMACEUTICALS INC

  公开号：WO2014110036A1

  公开（公告）日：2014-07-17

  Compounds of formula (I): [Formula should be inserted here]; where [Formula should be inserted here], n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.